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A B S T R A C T
Long term exposure to oral smokeless tobacco may induce lesions in the oral cavity characterized by a hyper-
plastic epithelium. The possible role of nicotine and the physical properties of oral tobacco for developing these
lesions, as well as of dysplasia and neoplasia is unclear. Low nitrosamine Swedish snus as well as non-genotoxic
butylated hydroxyanisole induces increased cellular proliferation in the rat forestomach epithelia. Using this
model, we report here on the effects of nicotine, pH, and particle size. Snus with different properties had no
impact on oxidative stress as determined by 8-oxo-7,8-dihydro-2′-deoxyguanosine, or on interleukin IL-1b.
Whereas BHA boosted IL-6, probably due to the presence of nicotine. there was no significant enhancement of
cell divisions with increasing particle size, although in individual samples the variations in proliferation rates
increased greatly with increasing particle size. Conforming to human experience, the enhanced cell proliferation
caused by snus was found to be completely reversible. A cacao bean extract had a protective action similar to
that previously found for blueberries. The main cause of the observed tobacco induced cell proliferation could be
mechanical irritation, possibly in combination with nicotine, whereas within the studied range, pH did not affect
the rate of cell division.
1. Introduction
During the last 3-4 decades male smoking-related deaths have gra-
dually decreased in Sweden. This development can to a major extent be
attributed to the fact that smoking has to a large extent been replaced
by nicotine delivery by a smokeless tobacco called “snus”. In spite of the
fact that about 20% of the adult male population uses snus regularly,
there is no convincing epidemiological evidence linking snus with an
elevated risk for cancers in the oral cavity, esophagus or stomach
(Lewin et al., 1998; Schildt et al., 1998; SCENIHR, 2008, p.11; Lee,
2011). Further, it has not been possible to verify the claim, that Swedish
snus causes pancreatic cancer (Lee, 2011; Bertuccio et al., 2011; Araghi
et al., 2017). In addition, in Sweden there has also been a drastic re-
duction in other smoking related diseases (Foulds et al., 2003; Lee,
2011, 2013).
The failure to detect an elevated cancer incidence in users of snus is
compatible with the fact that the levels of tobacco specific nitrosamines
(TSNA) are up 10,000 times lower than in impure carcinogenic
Sudanese oral tobacco (Idris et al., 1991, 1994; Österdahl et al., 2004;
WHO, 2009). Further, when comparing the expected levels of pro-
mutagenic TSNA-induced DNA damages induced by snus with the
“normal” background of the same lesions, no increase in cancer risk can
be expected (Nilsson, 2011, 2017). It has not been possible to induce
tumors in experimental animals using internationally recognized
methodology (Grasso and Mann, 1998).
After long term exposure snus may, nevertheless, induce local oral
lesions known as “snuff dipper's lesions”, leucoplakias, or snuff-induced
keratosis, characterized by a hyperplastic epithelium with vacuoliza-
tion and keratinization. Acanthosis and slight inflammation may also be
present accompanied by an increased mitotic rate (Larsson et al., 1991).
It should be distinguished from smoking induced preneoplastic forms of
leucoplakia displaying cellular atypia/dysplasia (Axéll, 1993; Axéll
et al., 1976; Andersson and Axéll, 1989). These dysplastic lesions are
typically induced by betel chewing, or by other impure tobacco pro-
ducts used in South East Asia and Sudan (Zain et al., 1997).
The smokeless tobacco keratosis induced by modern Swedish snus is
reversible after cessation of exposure, and has a very low probability for
malignant transformation (Larsson et al., 1991; Roosaar et al., 2006).
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Nevertheless, a carcinogenic risk associated with snus lesions in some
particularly susceptible individuals cannot be ruled out, although the
risk would be too low for reliable detection by conventional epide-
miological methods in view of residual confounding by smoking and
alcohol. However, these lesions represent a clinical problem in them-
selves. Snus users with leukoplakias are sometimes referred for various,
unnecessary clinical work ups, including surgical biopsy.
A number of potent carcinogens induce tumors in the rodent for-
estomach, which is also susceptible to the irritative or corrosive action
of several non-genotoxic compounds. In the latter case, stimulation of
cell division induced by cytotoxicity and regenerative hyperplasia re-
presents important underlying mechanisms (Clayson et al., 1991). In a
previous study we found that 4–6 weeks' exposure to snus administered
by oral intubation resulted in marked enhancement of hyperplasia and
cell divisions as assayed by bromodeoxyuridine (BrdU) in the rat sto-
mach epithelium (Allen et al., 1978). After 6 weeks' exposure, blue-
berries (bilberries), and an extract from the common milk thistle were
found to exert a highly significant inhibition of cell proliferation in-
duced by snus in the rat forestomach epithelium (Nilsson et al., 2016).
The possible role of nicotine and the physical properties of various
kinds of oral tobacco for development of oral dysplasia and neoplasia
have been extensively debated (Grasso and Mann, 1998; Andersson and
Warfvinge, 2003; Nilsson et al., 2016; Singh et al., 2018).
Although nicotine per se is not considered to be a carcinogen (EFSA,
2009), Sanner and Grimsrud (2015) have speculated that nicotine
promotes the induction of neoplasia by indirect mechanisms. The aim
of this experimental study was to investigate the influence of nicotine
content, pH, granularity as well as post treatment recovery on the in-
duction of rat forestomach hyperplasia induced by oral smokeless to-
bacco (Swedish snus). In addition, the protective action of an extract
from cacao beans and blueberries was investigated.
2. Materials and methods
2.1. bromodeoxyuridine (BrdU)
BrdU, 99%; Sigma Aldrich Co. USA) was purchased from Uni-Chem,
Belgrade. Flat-faced cylindrical matrices containing 50mg of BrdU with
a diameter of 5.6mm were prepared at the Faculty of Pharmacy,
Belgrade University, by a direct compression technique using an ec-
centric tablet press (Korsch EK-0, Korsch, Berlin, Germany).
2.2. Butylated hydroxyanisole (BHA)
BHA (99%) was obtained from Sigma/Aldrich Co., USA. It was
dissolved in corn oil (Sigma, Aldrich), and mixed with pulverized
commercial pellet (Veterinarian Institute Subotica, Serbia) to a final
concentration of 2%, and used as such.
2.3. Snus products
Snus with different physical and chemical characteristics was ob-
tained from Swedish Match AB. The concentration of selected
impurities are given below (Table 1) (Rutqvist et al., 2011). The levels
for nitrosamines and benzo(a)pyrene (B(a)P) conform to the limits re-
commended by WHO (2mg/kg for NNN plus NNK and 5 μg/kg for B(a)
P; WHO, 2009).
The following batches of experimental snus with different properties
were used in this study of the impact of physical properties on cellular
proliferation in the rat forestomach:
1 pH 8.5 (nicotine, 2.5%) mixed particle size (< 315, 315–500,
and> 500 μm)
2 pH 8.5 (nicotine, 1.2%) mixed particle size (< 315, 315–500,
and> 500 μm)
3 pH 8.5 (nicotine, 0.75%) mixed particle size (< 315, 315–500,
and> 500 μm)
4 pH 7.5 (nicotine, 1.2%) mixed particle size (< 315, 315–500,
and> 500 μm)
5 pH 9.5 (nicotine, 1.2%) mixed particle size (< 315, 315–500,
and> 500 μm)
6 pH 8.5 (nicotine, 1.2%) coaarse particle size (> 500 μm)
7 pH 8.5 (nicotine, 1.2%) medium particle size (315–500 μm)
8 pH 8.5 (nicotine, 1.2%) fine particle size (< 315 μm)
9 pH=8.5 (nicotine 0.75%), commercial snus (General) mixed par-
ticle size (< 315, 315–500, and> 500 μm)
The prescribed pH levels were achieved by adding appropriate
amounts of sodium carbonate to the experimental snus blends. The
prescribed nicotine concentrations of 0.75% and 1.2% were achieved
by using two different raw tobacco blends with the corresponding ni-
cotine contents. The nicotine concentration of 2.5% was achieved by
adding appropriate amounts of nicotine salt to the 1.2% blend. Both pH
and nicotine content in the finished experimental snus products was
confirmed analytically.
The variation of particle size distribution was achieved by sieving of
the ground, raw tobacco. The intermediate size experimental blend was
the one with the size distribution that most closely resembles that found
in most commercial snus brands. The typical particle size was in the
order of 2–400 μm and almost no particles exceeded 600 μm. The ty-
pical particle size in the “small particle size” blend was in the order of
50–150 μm with nearly no particles exceeding 300 μm. The “large
particle size” blend had a typical particle size in the order of
500–700 μm but with a large variation ranging from 5 to 1000 μm.
For the other investigations commercial snus (General, Swedish
Match) was used.
The tobacco was thoroughly homogenized with drinking water in a
blender, mixed in a vortex blender, and used as such. At high con-
centrations the tobacco slurry separated into two phases, which was
inappropriate for intubations. 10 g tobacco homogenized in 100ml of
H2O was found to be appropriate. 4 animals per group are given by
intubation of 1.5 ml snus suspensions 3 times a week for 6 weeks.
2.4. Blueberries (Vaccinium myrtillus)
As supplied by Frostab AB, Arvidsjaur, wild fresh berries were col-
lected in the north of Sweden and freeze dried at the Institute for Plant
Breeding at Balsgård, Swedish University of Agricultural Sciences,
Abbreviations
BHA Butylated hydroxyanisole
BrdU Bromodeoxyuridine
EFSA European Food and Safety Authority
IgG Immunoglobulin G
IL Interleukin
8-oxodG 8-oxo-7,8-dihydro-2′-deoxyguanosine
PI proliferation index
TSNA Tobacco specific nitrosamines
Table 1
- Impurities in Swedish snus. Average observed levels in Swedish Match's pro-
ducts (for year 2009).
Component Content Component Content
Nitrite (mg/kg) 2.0 (mg/kg) Cadmium (mg/kg) 0.6 (mg/kg)
TSNA total 1.6 (mg/kg) Lead 0.3 (mg/kg)
NDMAa 0.7 (μg/kg) Arsenic 0.1 (mg/kg)
B(a)P 1.1 (μg/kg) Nickel 1.3 (mg/kg)
a NDMA, N-nitrosodimethylamine.
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Kristianstad. The berries were ground, and 10 g of the powder was
mixed with 100ml drinking water and used in the current study.
2.5. Cacao extract
Roasted cacao beans from Swisslion Takovo, Gornji Milanovac,
were ground into a powder, of which 10 g was suspended in drinking
water and heated 15–20min at 50 °C to produce a liquor. The liquor
was filtered through sterile gauze, and mixed with equal volumes of a
slurry of pulverized tobacco and co-administered in the same gavage.
2.6. Chemical analysis
The total phenolic content of blueberries was performed using
UPLC, where gallic acid was used for calibration. The total amount of
polyphenols was about 20.2mg/g dry weight.
2.7. Animals and treatments
2.7.1. Experimental snus
Seven weeks old male inbred Wistar rats (250 ± 10 g) from sepa-
rate litters obtained from a colony at the Vinča breeding facility, were
maintained under standard conditions, group-housed (4 per cage) on
chip bedding with free access to food (pelleted commercial diet from
the Veterinarian Institute at Subotica, Serbia) and tap water, regular
12 h light/12 h dark cycle and constant temperature (21 ± 2 °C) and
humidity. Each individual animal was labeled with a unique identifi-
cation code printed with markers on the earlobes and tail. Body weights
were measured 3 times per week, and the animals observed daily for
signs of toxicity and behavioral changes. Volumes of 1.5ml containing
the tested agents described below were intragastrically intubated 3
times a week, for 6 weeks, using reusable stainless steel feeding needles,
3 mm ball diameter (Cadence Inc. USA).
Flat-faced cylindrical matrices containing 50mg of BrdU with a
diameter of 5.6mm were prepared by a direct compression technique
using an eccentric tablet press Korsch (Korsch EK-0, Korsch, Berlin,
Germany). The BrdU matrices were subcutaneously implemented in
dorsal neck region under chloral hydrate anesthesia (Allen et al., 1978).
2.7.2. Reversibility of snus induced changes
In addition to 6 control animals, 18 male Wistar rats were ad-
ministered 1.5ml snus (10 g snus homogenized in 100ml of drinking
water) by intragastric intubation 3 times a week for 6 weeks. 6 animals
were sacrificed on day 43, and the proliferation index, inflammatory
markers and micronuclei were determined. After cessation of snus ex-
posure, the remaining animals were put on a standard diet.
Subsequently, 6 animals were sacrificed on the weeks 12th and 18th
and the same analyses were repeated.
2.7.3. Protection of blueberries and cacao
Seven weeks old male Wistar rats were intragastrically intubated 3
times a week with slurry of snus supplemented with blueberries or
cacao as described in section 2.4 and 2.5, for 10 weeks. Animals were
sacrificed and target tissue analyzed as previously described, section
2.7.
10 g Samples of different types of Swedish snus were homogenized
in 100ml drinking water (c᷉a. 0.5 g/kg bw), and 10 groups of 6 rats were
treated with aliquots with characteristics described under “2.2 Snus
products” including BHA for 6 weeks, a group given BHA, as well as an
untreated control group. Sacrifice was done on day 43.
All procedures for treatment of the animals were approved by the
Ethical Committee for the Use of Laboratory Animals of the Vinča ac-
cording to the guidelines issued by the EU registered Serbian
Laboratory Animal Science Association implementing the European
Communities Council Directive of 24 November 1986 (86/609/EEC) as
well as the rules for good laboratory practice established by EU and
OECD. All animal experiments are under the guidance of an authorized
veterinarian specialized in the conduction of animal experiments, and
the principal investigators and technicians are authorized to perform
experiments in animals.
2.8. Blood sampling
Rat blood samples were allowed to clot for 1 h under refrigeration.
The samples were centrifuged for 20min at 1000 g, and the serum di-
vided in 4 cryotubes 0,5ml each, and kept at −80 °C until measure-
ment.
2.9. Autopsy and tissue preparation
The animals were sacrificed by decapitation 24 h after the last ga-
vage treatment, and the stomachs with the parts of upper small intes-
tine were removed. The forestomachs were separated (near the limiting
ridge) and cut along the minor curvature. During target tissue separa-
tion, the animals' abdominal and thoracic organs were inspected for any
pathological changes. After separation, forestomachs were washed in
0.9% aqueous sodium chloride, spread on paraffin substrate with pins
and covered with 10% neutral buffered formalin for one week's fixa-
tion. Tissue blocks of the forestomach were cut transversely into serial
sections 5 μm in thickness from the forestomach middle region. Two
consecutive sections in the range of 250mm between each level, were
taken for analysis. The tissue sections were stained with hematoxylin
and eosin for histological analysis and immunohistochemically for the
incorporation of BrdU into DNA for analysis of cell proliferation. The
analysis was done at magnifications 10x and 20x.
Because the forestomach-esophageal junction and the middle region
were found to exhibit the highest levels of incorporation in our previous
study (Nilsson et al., 2016), sections from the middle region were se-
lected for the BrdU analysis.
2.10. Cell proliferation study
After deparaffinization in xylene, dehydration with a series of de-
creasing concentrations of ethanol, and rehydration in drinking water,
the forestomach sections were stained immunohistochemically
(Pharmingen™ BD Biosciences®, San Jose, CA, USA). Basically, the
procedure involves the use of a monoclonal antibody against BrdU
(anti-BrdU murine IgG), which is detected with a secondary antibody
(biotinylated goat anti-mouse IgG) linking the primary antibody to a
label (streptavidin-HRP) as the detection system, and 3,30-diamino-
benzidine as chromogen for visualization of BrdU incorporation (BD
Biosciences, 2014). The forestomach tissue sections incubated with
normal serum instead of the primary antiserum were used for control
staining. The sections were counterstained with Mayer's hematoxylin
(Merck) for analysis under light microscope. Proliferating BrdU positive
cells are found in the basal layer and granulose layers of squamous
epithelium.
The number of immunoreactive cells in the squamous stratified
epithelium was determined using a computer-supported imaging
system connected to a light microscope with an objective magnification
of 10x. BrdU positive cells were expressed per mm2 of epithelium. The
area of the epithelium was calculated using the following expression:
P= p x d2/106
Here, P is the surface area, p is the number of grid points that lie in
the epithelium, and d is the size of the square network at a magnifi-
cation of 200 (10x objective). The number of proliferating (BrdU) cells
was expressed per mm2 of epithelium, and calculated according to the
expression N=n/P, where n is the number of BrdU positive cells on the
presented surface, and P is the examined surface area of epithelium.
From each animal tissue sections were scored in the forestomach-
G. Joksić, et al. Regulatory Toxicology and Pharmacology 104 (2019) 21–28
23
middle region. In addition to the number of BrdU positive cells/mm2,
the ratio between dividing cells and the total number of cells per unit
area (proliferation index, PI), expressed as percentage is given. This
enabled a comparison to be made between the two manners of pre-
sentation.
2.11. Induction of micronuclei
6 rats were given commercial snus for up to 10 weeks. Micronuclei
were scored in the forestomach tissue prepared as described in section
2.9.
For each sample 1000 BrdU stained cells were scored and micro-
nuclei were recorded using a Zeiss microscope (400X or 1000X). The
criteria for identifying micronuclei were as follows:1) BrdU positive
staining with intensity similar to that of the nucleus (2) less than one-
third of the diameter of the associated nucleus located outside the nu-
cleus; (3) texture similar to that of the nucleus.
2.12. Effects on interleukins
Interleukins were determined in blood samples collected on day 43.
For measurement of IL-1β, the Quantikine Elisa Immunoassay was used,
a quantitative sandwich enzyme immunoassay that contains a poly-
clonal antibody specific for rat IL-1β, pre-coated onto a microplate,
HRP conjugated secondary antibody and a colorimetric detection sub-
strate. Concentration was determined spectrophotometrically according
to standard curve using Tecan Sunrise microplate reader. For determi-
nation of IL-6, the Quantikine Elisa Immunoassay was used,
Immunoassay was used, the design of which is similar to that for IL-1β.
2.13. Effects on oxidative stress
For measurement of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-
oxodG) in serum, the HT 8-oxo-dG ELISA Kit (Trevigen®, Gaithersburg,
MD, USA), was used, which employs an anti-8-oxo-dG monoclonal
mouse antibody, an HRP conjugated secondary antibody, and a col-
orimetric detection substrate. Concentration was determined spectro-
photometry (Tecan Sunrise microplate reader).
2.14. Statistical analysis
The results are expressed as the mean ± SD. Values were compared
using the nonparametric Mann-Whitney U test in the program SPSS 10
for Windows. The biostatisticians J.S. Fry and P.N. Lee, London, were
consulted for an in depth analysis of the apparently complex association
between nicotine concentration and PI. In addition to parametric sta-
tistics (F-test) and a Pearson correlation coefficient, the Spearman non-
parametric correlation coefficient based on the ranks of the values, as
well as the Kendall tau correlation coefficient were used.
3. Results
3.1. Body weight (BW) gain
There were no significant gross pathological alterations in controls
or in the treated animals, nor was any evidence of an inflammatory
response detected. As demonstrated in Table 2, the BW gain of the rats
indicated no treatment related excessive general toxicity that could
have been induced e.g. by nicotine. For samples 7 and 8 with 1.2%
nicotine the BW gains in treated rats were actually higher than in
controls. The small decrease in BW gain in the sample with 2.5% is
statistically not significant. The observed variations for these small
groups of animals were not significant (Mann-Whitney test), were
within the normal range, and could not be related to the physical
properties of the different batches.
3.2. Effects on proliferation of nicotine, pH and particle size
The following conclusions may be drawn with respect specific snus
characteristics (Table 2):
pH in the range 7.5–9.5 did not influence PI, and the levels of 8-oxo-
dG or IL-1β were unaffected. The data for IL-6 were characterized by
high inter-individual variations. However, whereas BHA treatment in-
creased this cytokine, the levels were significantly depressed by treat-
ment with snus, where the value for sample 3 was exceptionally low.
For nicotine some differences at different concentrations were evi-
dent using both parametric and non-parametric analyses. Based on all
48 data points, parametric statistics (F-test) gave a significant positive
correlation (p=0.0019) with the increase in PI per percent nicotine,
estimated as 5.514 (SE 1.678). This was confirmed using a Pearson
correlation coefficient. However, an additional analysis using a
Spearman non-parametric correlation coefficient based on the ranks of
the values, the p value was no longer significant at p=0.1257. Nor was
it significant (p=0.1542) using a Kendall tau correlation coefficient.
Nevertheless, in comparison with snus containing 0.75%, the PI for
samples with 2.5% nicotine was higher, although there was no sig-
nificant increase between 0.75% and 1.2%.
The trend for augmented rates of cell divisions with increasing
coarseness was statistically not significant, although the variations in PI
in individual samples increased greatly with increasing particle size
(Fig. 1). In contrast to snus with fine particles (< 315 μm) as well as
BHA treatment, administration of coarse snus resulted in an uneven
distribution of foci with high, respective low rates of cell proliferation
(Fig. 2).
3.3. Induction of micronuclei (MN)
See Table 4.
Table 2
Body weight (BW) of the animals at the beginning and the end of 6 weeks of treatment with BHA or batches of snus with different characteristics.
Experimental batch No. (nicotine %; pH) BW (g) 0 weeks of treatment BW (g) 6 weeks of treatment BW gain (g) at 6 weeks
Controls 255 ± 5 430 ± 22 165
BHA 255 ± 5 413 ± 40 158
1 (2.5%; pH 8.5) mixed particle size 247 ± 3 405 ± 35 158
2 (1.2%; pH 8.5) mixed particle size 243 ± 6 370 ± 36 127
3 (0.75%; pH 8.5) mixed particle size 250 ± 9 418 ± 31 168
4 (1.2%; pH 7.5) mixed particle size 250 ± 10 395 ± 36 145
5 (1.2%; pH 9.5) mixed particle size 243 ± 8 375 ± 38 132
6 (1.2%; pH 8.5) coaarse particle size 250 ± 5 385 ± 30 135
7 (1.2%; pH 8.5) medium particle size 250 ± 5 440 ± 17 190
8 (1.2%; pH 8.5) fine particle size 255 ± 0 445 ± 18 190
Commercial snus (0.75%; pH 8.5) mixed particle size 255 ± 5 400 ± 26 145
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3.4. Protective effects
The protective effect of blueberries described before (Nilsson et al.,
2016) could be verified in this study. In addition, an extract from cacao
beans proved to be equally efficient in suppressing forestomach hy-
perplasia induced by commercial snus (Table 5, Fig. 3).
3.5. Reversibility
Already after 6 weeks recovery post-treatment, there was a sig-
nificant reduction in the number of dividing cells, and after 12 weeks
the values were identical with those seen for controls (Table 6). These
results agree with the corresponding microphotographs (Fig. 4, mag-
nification 40x).
4. Discussion
Based on promotion of cell division (proliferation index, PI) in the
rat forestomach, the impact of Swedish smokeless tobacco (snus) was
investigated systematically with respect to reversibility, nicotine con-
tent, pH, particle size, oxidative stress, the inflammatory interleukins
IL-1β and IL-6. This seems to be the first study of this kind to be pub-
lished. The non-genotoxic BHA as well as all snus samples induced
cellular proliferation in the forestomach epithelia, and whereas pH did
not seem to affect the rate of cell division, mechanical irritation, pos-
sibly in combination with nicotine, could represent main causes.
A clear cut result was obtained in the experiments related to re-
versibility (Fig. 5; Table 6). In line with human experience (Larsson
et al., 1991), the enhanced cell proliferation caused by snus was found
to be completely reversible. Further, there was a concordance between
the effects on cell proliferation as measured by the uptake of BrdU in
DNA and the impact on relevant molecular growth factors and bio-
markers for cellular signaling. The results provide good evidence for the
relevance of the animal model used.
Mainly because it has been relatively easy to analyze, 8-oxo-7,8-
dihydro-2′-deoxyguanosine (8-oxo dG) is the most extensively studied
marker of oxidative DNA damage. The absence of any impact on oxi-
dative stress as monitored by 8-oxo dG, as well as on the levels of the
proinflammatory cytokine IL-1β, was noteworthy. One possible ex-
planation for the absence of an effect on 8-oxo dG could be that the
forestomach tissue mass relative to total body mass was not rather
adequate to detect oxidative stress biomarker in blood.
In users of smokeless tobacco an increased frequency of micronuclei
(MN) in exfoliated cells from the oral cavity epithelia has been reported
(Livingston et al., 1990; Trivedi et al., 1993; Ozkul et al., 1997). Un-
fortunately, the TSNA content of the tobacco used was not provided.
The Swedish snus with a very low level of TSNA used in our study did
not enhance the frequency of MN. The inhibition of MN induction
caused by BHA can probably be ascribed to its antioxidant properties.
When combining three different characteristics of the tested snus
(Table 3), this resulted in few data points for the batches with a low
respective high nicotine content, as well as for snus with fine, inter-
mediary and coarse granulation. The resource demanding nature of
these studies posed a limit to the number of different types of snus that
could be processed. There was a statistically non-significant trend for
enhanced rates of cell divisions with increasing coarseness, There was a
trend for enhanced rates of cell divisions with increasing coarseness,
although the variations in PI in individual samples increased greatly
with increasing particle size (Fig. 1). Whereas the SD of the PIs for
finely granulated snus (particle size< 315 μm), as well as for BHA,
were similar to that found for controls, the SDs were very large for snus
with mixed particle size and granular size greater than 500 μm. An
uneven distribution of focal centers with high and low rates of cell
proliferation no doubt resulted in the highly variable PI values (Fig. 2).
Scoring dividing cells in combined homogenates from different sections
of the epithelium might provide a more coherent picture.
EFSA (2009) has concluded that nicotine is not a carcinogen, but a
higher pH in smokeless tobacco has been reported to increase nicotine
uptake (Pickworth et al., 2014). Sanner and Grimsrud (2015) have
speculated that nicotine may enhance the induction of cancer by en-
dogenous conversion to tobacco specific nitrosamines (TSNA), and/or
by acting as a promoter. In comparison with the TSNA levels present in
snus, not to mention the doses of TSNA required in bioassays to induce
tumors, the actual conversion of nicotine to NNK (and NNN) is negli-
gible in experimental animals (Carmella et al., 1997) as well as in hu-
mans (Hatsukami et al., 2004; Stepanov et al., 2009). Further, our study
as well as in vivo data from adequately performed studies on promotion
(Murphy et al., 2011) provide little evidence to support the claims of
Sanner and Grimsrud (2015).
Fig. 1. Effect of tobacco particle size in the range<315 to> 500 μm on the
proliferation index (PI) in epithelial sections of the rat forestomach.
Fig. 2. Microphotographs showing the effects of treatment
with (a) BHA for 6 weeks as compared to treatment with (b)
commercial snus for 6 weeks with a particle size> 500 μm.
Black-brown colored cells represent proliferative (BrdU in-
corporated) cells. (Magnification 40x). (For interpretation of
the references to color in this figure legend, the reader is
referred to the Web version of this article.)
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In comparison with snus containing 0.75% nicotine there was a
small, but statistically significant increase of PI for exposure to snus
with 2.5% nicotine, although no significant impact on PI could be found
in the range 0.75% and 1.2%. However, it may be premature to draw
definite conclusions about the dose-effect relationship in view of the
fact that 36 animals were treated with snus with nicotine 1.2%, but
only groups of 6 animals were exposed each to 0.75% and 2.5%. Under
our experimental conditions, pH in the range 7.5–9.5 did not influence
PI, and there was no indication of increased oxidative stress as mea-
sured by 8-oxo dG.
Snus-induced hyperplasia could be expected to be accompanied by
an inflammatory response. For this reason the cytokines interleukin 1
and 6 were monitored. However, the levels of inflammatory cytokine
IL-1β were not affected. The positive control BHA enhanced the pro-
duction of IL-6, and it was expected that tobacco would have a similar
action, but the effect was found to be the opposite. This can most
probably be related to the presence of nicotine in snus. Thus, it has been
reported that nicotine suppresses IL-6 production from vascular en-
dothelial cells (Tarantula et al., 2010), as well as in lipopolysaccharide
activated human coronary artery endothelial cells and pulmonary
monocytes (Patton et al., 2006).
Dietary cacao flavanols improve major hallmarks of cardiovascular
function including blood pressure and blood cholesterol, and the posi-
tive effects in humans have been unequivocally established and re-
cognized by EU (EFSA, 2014; EU, 2015). We have demonstrated that
cacao, in addition, has a protective effect against snus-induced cell
proliferation in the rat forestomach which equals that of the blueberries
from northern Sweden (Fig. 3; Table 5), which had a considerably
higher concentration of polyphenols than e.g. found in cultivated
blueberries (Sellappan et al., 2002).
5. Conclusions
Low nitrosamine Swedish snus, as well as non-genotoxic butylated
hydroxyanisole (BHA), induce increased cellular proliferation in the rat
forestomach epithelia. Snus with different properties, such as pH, ni-
cotine and particle size, had no significant impact on oxidative stress as
determined by 8-oxo-7,8-dihydro-2′-deoxyguanosine, or on interleukin
IL-1β. Whereas BHA boosted IL-6, it was depressed for all snus samples,
probably due to the presence of nicotine. There was a statistically non-
significant trend of increased cell divisions with increasing particle
Table 3
Proliferation indices (PI), levels of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG), interleukins IL1 beta and IL6 for the various types of experimental snus ad-
ministered for 6 weeks. Bromodeoxyuridine (BrdU) incorporation was determined in the forestomach mid region. Butylated hydroxyanisole (BHA) served as positive
control.
Experimental batch No. (nicotine %; pH) PI 8-oxo-dG. nM IL-1β pg/mL IL-6 pg/ml
Controls 23.37 ± 3.1a 0.88 ± 0.12 50.66 ± 4.82 45.40 ± 14.49
1 (2.5%; pH 8.5) mixed particle size 43.05 ± 7.04b 1.09 ± 0.45 47.73 ± 2.21 25.50 ± 4.59
2 (1.2%; pH 8.5) mixed particle size 33.64 ± 2.26c 1.18 ± 0.07 54.91 ± 2.77 18.83 ± 3.37
3 (0.75; pH 8.5) mixed particle size 35.14 ± 2.39d 1.34 ± 0.98 49.11 ± 1.03 7 ± 1.55
4 (1.2%; pH 7.5) mixed particle size 32.16 ± 2.27 1.03 ± 0.04 46.45 ± 1.88 23.08 ± 6.03
5 (1.2%; pH 9.5) mixed particle size 34.8 ± 8.4 0.82 ± 0.16 49.53 ± 2.75 25.83 ± 8.9
6 (1.2%; pH 8.5) coarse particle size 37.43 ± 8.45e 1.03 ± 0.16 50.55 ± 0.96 41.2 ± 3.37
7 (1.2%; pH 8.5) medium particle size 31.62 ± 6.29 0.54 ± 0.13 49.71 ± 2.43 14.83 ± 5.54
8 (1.2%; pH 8.5) fine particle size 33.67 ± 1.47 0.76 ± 0.03 49.91 ± 0.36 18.0 ± 0
Commercial snus (0.75%; pH 8.5) mixed particle size 37.24 ± 2.69f 1.06 ± 0.18 49.4 ± 1.76 32.5 ± 11
BHA 73.12 ± 2.61g 1.13 ± 0.02 55.8 ± 1.39 64.33 ± 3.18h
a p < 0,01, control vs. Experimental batches 1-8.
b p < 0.001, Experimental batch 1 vs. Experimental batches 2–5, 7 and 8.
c p < 0.01, Experimental batch 1 vs. Experimental batches 5 and 6.
d p < 0.05, Experimental batch 3 vs. Experimental batch 6.
e p < 0.01, Experimental batch 6 vs. Experimental batches 4 and 7.
f p < 0.025 Commercial snus vs. Experimental snus 1.
g p < 0.001, BHA vs. Experimental batches 1-8.
h p < 0.01, BHA vs. Experimental batches 1-8.
Table 4
Induction of micronuclei (MN) in the rat forestomach epithelium after treat-
ment with commercial snus for 4, 6, 8 and 10 weeks in comparison with con-
trols and BHA (10 weeks).
Duration of
treatment
Incidence of MN per 1000
BrdU stained cells (SNUS)
Incidence of MN per 1000
BrdU stained cells (BHA)
0 (Control) 0,0028 0,0038
4 weeks 0,0036
6 weeks 0,0036
8 weeks 0,004
10 weeks 0,0036 0,0018
The MN frequencies were low upon exposure to snus, and there was no sig-
nificant trend (Man-Whitney test). The depression induced by BHA also was
statistically insignificant (p < 0.248).
Table 5
Protective effects against hyperplastic effects induced by commercial snus in epithelial sections of the rat forestomach by blueberries and a cacao extract, and
measured as proliferation index (PI). Bromodeoxyuridine (BrdU) incorporation was determined in the forestomach mid region. Butylated hydroxyanisole (BHA)
served as positive control.
Group PI 8-oxo dG nM IL-1β pg/mL IL-6 pg/mL
Snus 10 weeks 42.15 ± 8.16 1.57 ± 0.44 78.71 ± 5.4 76.52 ± 9.69
Snus + Blueberries 26.52 ± 5.52a 0.93 ± 0.13 52.27 ± 2.56 38.00 ± 21.94
Blueberries 16.68 ± 0.86 1.02 ± 0.16 55.69 ± 2.53 26.5 ± 3.83
Snus + Cacao 26.92 ± 0.89a 1.25 ± 0.07 53.54 ± 1.95 32.08 ± 13.09
Cacao 27.99 ± 1.28 1.05 ± 0.18 54.13 ± 3.04 22.67 ± 4.5
BHA 10 weeks 82.94 ± 7 1.30 ± 0.01 51.86 ± 2.10 45.5 ± 8.28
ap< 0.001, significantly lower than snus 6 weeks.
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coarseness, although the variations in proliferation index increased
greatly with increasing particle size, evidently due an uneven dis-
tribution of foci with a high rate of cell proliferation. In comparison
with snus containing 0.75%, the rate of cell proliferation was higher for
samples with 2.5% nicotine, although there was no significant increase
between 0.75% and 1.2%. Administration of snus for up to 10 weeks
resulted in a moderate increase in the frequency of micronuclei.
In line with human experience, the enhanced cell proliferation
caused by snus was found to be completely reversible. A cacao bean
extract had a protective action similar to that previously found for
blueberries.
The main cause of the observed tobacco induced cell proliferation
seems to be mechanical irritation, possibly in combination with nico-
tine.
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